Aromatic l-amino acid decarboxylase deficiency in Taiwan.
Paul Wuh-Liang HwuRai-Hseng HsuMei-Hsin LiHui-Min LeeHui-An ChenNi-Chung LeeYin-Hsiu ChienPublished in: JIMD reports (2023)
Aromatic l-amino acid decarboxylase (AADC) deficiency is a rare inherited disorder that affects neurotransmitter biosynthesis. A DDC founder mutation c.714 + 4A > T (IVS6 + 4A > T) is prevalent in the Chinese population. This study investigated the epidemiology of AADC deficiency in Taiwan by analyzing data from National Taiwan University Hospital (NTUH), a central institution for diagnosing and treating the disease. From January 2000 to March 2023, 77 patients with AADC deficiency visited NTUH. Among them, eight were international patients seeking a second opinion, and another two had one or both non-Chinese parents; all others were ethnically Chinese. The c.714 + 4A > T mutation accounted for 85% of all mutated alleles, and 94% of patients exhibited a severe phenotype. Of the 77 patients, 31 received gene therapy at a mean age of 3.76 years (1.62-8.49) through clinical trials, and their current ages were significantly older than those of the remaining patients. Although the combined incidence of AADC deficiency in this study (1:66491 for 2004 and later) was lower than that reported in newborn screening (1:31997 to 1:42662), case surges coincided with the launch of clinical trials and the implementation of newborn screening. Currently, many young patients are awaiting for treatment.
Keyphrases
- end stage renal disease
- ejection fraction
- clinical trial
- chronic kidney disease
- amino acid
- prognostic factors
- healthcare
- primary care
- randomized controlled trial
- physical activity
- risk factors
- high resolution
- quality improvement
- big data
- gene therapy
- early onset
- combination therapy
- patient reported
- phase ii
- community dwelling
- drug induced